EUVIMEDEUVIMED entdecken
Crossref

Expanding the Molecular Characterization of Adenoid Ameloblastoma by Assessing a Panel of Oncogenes and Tumor Suppressor Genes

Ygor G Fonseca, Victor C Bastos, Rennan G Moreira, Felipe P Fonseca, Pablo A Vargas, John M Wright, Renato S Aguiar, Edward W Odell, Ricardo S Gomez, Letícia M Guimarães, Carolina C Gomes

Modern Pathology · 2026-01 · 39 (1) · 100920

DOI: 10.1016/j.modpat.2025.100920 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026-01. Verfasst von Ygor G Fonseca und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Biological Sciences Institute, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. Hauptthemen laut MEDLINE: Ameloblastoma, Oncogenes, Genes, Tumor Suppressor, Biomarkers, Tumor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Universidade Federal de Minas Gerais.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adenoid ameloblastoma (AA) is a rare epithelial odontogenic tumor microscopically characterized by ameloblastoma-like epithelium, duct-like structures, epithelial whorls, cribriform architecture, and dentinoid matrix. Wnt/β-catenin activation, usually by CTNNB1 mutations, is thought to characterize AA, which are BRAF and KRAS wild type. The present study aimed to expand the genetic characterization of AA by interrogating variants at several sites known to be linked to solid tumor pathogenesis. Six AA samples were sequenced at an unprecedented sequencing depth using a 22-gene panel including oncogenes and tumor suppressor genes commonly mutated in solid human tumors, namely AKT1, ALK, BRAF, CTNNB1, EGFR, ERBB2, ERBB3, ESR1, FOXL2, GNA11, GNAQ, IDH1, IDH2, KRAS, KIT, MET, NRAS, PDGFRA, PIK3CA, RAF1, RET, and TP53. Reinforcing the distinct molecular identity of AA, absence of BRAF p.Val600Glu and KRAS p.Gly12Val/Arg mutations was observed. CTNNB1 mutations were identified in 4 of 6 cases (67%), including previously reported variants (p.Ser33Cys and p.Gly34Arg) as well as novel ones (p.Leu31Leu and p.Gln68∗), supporting the involvement of the Wnt/β-catenin signaling pathway in AA pathogenesis. In 2 cases, CTNNB1 variants co-occurred with either TP53 or ERBB2 and PIK3CA variants, suggesting potential secondary oncogenic events. Notably, in 2 cases, no variants were detected. Our findings provide further evidence for AA classification as a separate tumor entity. The identification of previously reported CTNNB1 and novel genetic variants contributes to better characterization of the molecular profile of AA. Future studies are required to interrogate variants in other genes in wild-type cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmeloblastomaOncogenesGenes, Tumor SuppressorBiomarkers, TumorJaw NeoplasmsHumansFemaleMaleAdultMiddle AgedMutationDNA Mutational AnalysisYoung Adult

Stichwörter der Autor:innen

BRAFCTNNB1KRASWnt/β-catenin pathwayadenoid ameloblastomaodontogenic tumor

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Biological Sciences Institute, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
  • Genomics Laboratory, Multiuser Laboratories Center, Biological Sciences Institute, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
  • Department of Oral Pathology and Medicine, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
  • Oral Diagnosis Department, Piracicaba Dental School, Universidade Estadual de Campinas, Piracicaba, Brazil.
  • Diagnostic Sciences Department, Texas A&M University College of Dentistry, Dallas, Texas.
  • Department of Genetics, Ecology and Evolution, Biological Sciences Institute, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.

Förderung

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais
  • Universidade Federal de Minas Gerais
  • CNPq

Zitieren

APA

Fonseca, Y. G., Bastos, V. C., Moreira, R. G., Fonseca, F. P., Vargas, P. A., Wright, J. M., Aguiar, R. S., Odell, E. W., Gomez, R. S., Guimarães, L. M., & Gomes, C. C. (2026). Expanding the Molecular Characterization of Adenoid Ameloblastoma by Assessing a Panel of Oncogenes and Tumor Suppressor Genes. Modern Pathology, 39(1), 100920. https://doi.org/10.1016/j.modpat.2025.100920

Vancouver

Fonseca YG, Bastos VC, Moreira RG, Fonseca FP, Vargas PA, Wright JM, et al. Expanding the Molecular Characterization of Adenoid Ameloblastoma by Assessing a Panel of Oncogenes and Tumor Suppressor Genes. Modern Pathology. 2026;39(1):100920. doi:10.1016/j.modpat.2025.100920

BibTeX
@article{Fonseca2026,
  author = {Fonseca, Ygor G and Bastos, Victor C and Moreira, Rennan G and Fonseca, Felipe P and Vargas, Pablo A and Wright, John M and Aguiar, Renato S and Odell, Edward W and Gomez, Ricardo S and Guimarães, Letícia M and Gomes, Carolina C},
  title = {Expanding the Molecular Characterization of Adenoid Ameloblastoma by Assessing a Panel of Oncogenes and Tumor Suppressor Genes},
  journal = {Modern Pathology},
  year = {2026},
  volume = {39},
  number = {1},
  pages = {100920},
  doi = {10.1016/j.modpat.2025.100920}
}
Kostenlos starten →